Business Description
Clinica Baviera SA
ISIN : ES0119037010
Description
Clinica Baviera SA operates ophthalmological clinics. It is involved in the diagnosis, treatment, and monitoring of various types of ophthalmological disorders. It offers diagnosis and treatment for various eye problems such as long-sightedness, short-sightedness, astigmatism, cataracts and eye strain.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.08 | |||||
| Equity-to-Asset | 0.51 | |||||
| Debt-to-Equity | 0.52 | |||||
| Debt-to-EBITDA | 1.59 | |||||
| Interest Coverage | 110.96 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 5.02 | |||||
| Beneish M-Score | -2.95 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 22.4 | |||||
| 3-Year EBITDA Growth Rate | 25.2 | |||||
| 3-Year EPS without NRI Growth Rate | 37.5 | |||||
| 3-Year FCF Growth Rate | 14.1 | |||||
| 3-Year Book Growth Rate | 26.9 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 68.54 | |||||
| 9-Day RSI | 59.17 | |||||
| 14-Day RSI | 57.08 | |||||
| 6-1 Month Momentum % | 43.28 | |||||
| 12-1 Month Momentum % | 53.19 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.28 | |||||
| Quick Ratio | 1.22 | |||||
| Cash Ratio | 1.13 | |||||
| Days Sales Outstanding | 11.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.8 | |||||
| Forward Dividend Yield % | 4.55 | |||||
| 5-Year Yield-on-Cost % | 2.8 | |||||
| Shareholder Yield % | 3.75 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | 19.04 | |||||
| Net Margin % | 13.75 | |||||
| FCF Margin % | 12.79 | |||||
| ROE % | 19.06 | |||||
| ROA % | 8.89 | |||||
| ROIC % | 11.23 | |||||
| ROC (Joel Greenblatt) % | 22.64 | |||||
| ROCE % | 16.33 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 30.9 | |||||
| PE Ratio without NRI | 30.9 | |||||
| Shiller PE Ratio | 29.06 | |||||
| Price-to-Owner-Earnings | 24.76 | |||||
| PEG Ratio | 1.25 | |||||
| PS Ratio | 4.25 | |||||
| PB Ratio | 5.09 | |||||
| Price-to-Tangible-Book | 6.33 | |||||
| Price-to-Free-Cash-Flow | 33.18 | |||||
| Price-to-Operating-Cash-Flow | 16.42 | |||||
| EV-to-EBIT | 22.18 | |||||
| EV-to-EBITDA | 15.52 | |||||
| EV-to-Revenue | 4.24 | |||||
| EV-to-FCF | 32.92 | |||||
| Price-to-Projected-FCF | 1.73 | |||||
| Price-to-DCF (Earnings Based) | 0.9 | |||||
| Price-to-DCF (FCF Based) | 0.97 | |||||
| Price-to-Median-PS-Value | 2.51 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.51 | |||||
| Price-to-Graham-Number | 2.54 | |||||
| Earnings Yield (Greenblatt) % | 4.51 | |||||
| FCF Yield % | 2.99 | |||||
| Forward Rate of Return (Yacktman) % | 17.71 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers